Leading the Pathway to Better Cancer Therapies

Cancer patients throughout the world are in urgent need of better treatment options. At ARIAD, we believe the way to breakthrough cancer therapies for many forms of cancer is through the regulation of cell-signaling pathways. We are building a fully integrated oncology company focused on novel, molecularly targeted therapies to treat solid tumors and hematologic cancers, as well as the spread of primary tumors to distant sites. Our business strategy is to:

• build a fully integrated oncology company and become a leader in the discovery, development and commercialization of molecularly targeted oncology therapies;
• broadly develop our lead oncology product candidates and build a pipeline of innovative follow-on product candidates;
• enter into partnerships with major pharmaceutical or biotechnology companies, after obtaining definitive clinical data, to assist in developing our cancer product candidates and commercializing them in selected markets;
• license our NF-κB and ARGENT cell-signaling regulation technologies to pharmaceutical and biotechnology companies; and
• leverage the market potential of our product candidates by licensing them to other companies for development and commercialization in non-oncology indications or non-core applications.